controversy news from FierceBiotech

Further evidence of Texas' growing power in the biotech industry: the Austin Business Journal reports that in recent months, central Texas-based life science outfits have attracted about $500 million... Read more...

With cases of antibiotic-resistant MRSA multiplying and fear of the superbug rising, Cepheid... Read more...

When is a cancer therapy good enough? The Boston Globe examines answers to that question following the recent controversy over the FDA's decisions in the field. Most recently, Avastin gained a new... Read more...

A bubbling controversy over a clinical trial for a new device to cure back pain is being used to highlight how conflicts arise when researchers stand to gain financially from an experimental... Read more...

> Cardiome is awaiting a critical FDA decision on its drug vernakalant. Report > It seems that many black U.S. residents... Read more...

Scientists in California made embryo clones of two men, a step toward developing new stem cells for therapeutic purposes. But a number of experts quickly noted that cloned embryos of humans have been... Read more...

The Reagan-Udall Foundation was created by Congress to ramp up innovation in drug science, help... Read more...

With a fresh controversy swirling around newly appointed Executive Director Robert Coughlin, the Massachusetts Biotechnology Council is being hit with criticism from its own members concerned that... Read more...

Texas voters will have the final say on a proposed $3 billion effort to support cancer research over 10 years inside the Lone Star state. This is the brainchild of the governor, who's clearly... Read more...

Gilead is reporting that a Phase III trial of its HIV drug Viread was more effective at reducing amounts of the hepatitis B virus than the company's other antiviral drug, Hepsera. At 48 weeks, 66.5 percent receiving Viread had a complete response compared to 12.2 percent in the Hepsera arm. "The preliminary data observed in both Phase III trials evaluating Viread as a potential treatment option for chronic hepatitis B are very encouraging," said Franck Rousseau, MD, Vice President, …

... Read more...